Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of second primary cancer after radiotherapy for localized prostate cancer: A single-center Korean cohort study.

Investigative and clinical urology·2026
Same authorSame journal

Clinical Outcomes of Endoscopic Resection for Gastric and Duodenal Neuroendocrine Tumors.

Gut and liver·2026
Same author

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.

Gut and liver·2026
Same author

Cardiovascular Disease in Chronic Kidney Disease: Ethnic and Regional Differences in Risk and Phenotype.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Retrospective External Validation of the ELAPSS Score for the Prediction of Unruptured Intracranial Aneurysm Growth Risk.

Current neurovascular research·2026
Same author

Clinical and Molecular Genetic Risk Factors for Severe Familial Hypercholesterolemia.

Journal of lipid and atherosclerosis·2026

Related Experiment Video

Updated: Jun 27, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Proton Pump Inhibitors and Gastric Cancer: A Large-Scale Propensity Score-Matched Analysis.

Cheal Wung Huh1, Nak-Hoon Son2, So Hyeon Gwon2

  • 1Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.

Gut and Liver
|June 25, 2026
PubMed
Summary
This summary is machine-generated.

Proton pump inhibitor (PPI) use is linked to a higher risk of gastric cancer compared to non-users or histamine-2 receptor antagonist (H2RA) users. Long-term PPI use warrants caution due to this association.

Keywords:
Histamine H2 antagonistsProton pump inhibitorsStomach neoplasms

More Related Videos

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Proton pump inhibitors (PPIs) are widely used for acid-related gastrointestinal disorders.
  • Concerns exist regarding potential long-term adverse effects of PPIs, including cancer risk.

Purpose of the Study:

  • To investigate the association between proton pump inhibitor (PPI) use and the risk of developing gastric cancer.
  • To compare gastric cancer incidence in PPI users versus non-users and histamine-2 receptor antagonist (H2RA) users.

Main Methods:

  • A population-based cohort study utilizing UK Biobank data (1990-2016).
  • Propensity score matching was employed to compare new PPI users with non-PPI users and H2RA users.
  • Cox proportional hazards models were used to assess gastric cancer incidence, with secondary analyses on duration and dose-response.

Main Results:

  • PPI users exhibited a 2.32-fold higher risk of gastric cancer compared to non-PPI users (HR 2.324).
  • The risk was even higher when compared to H2RA users (HR 5.343).
  • Gastric cancer risk increased with longer PPI duration and higher cumulative doses, with results robust across sensitivity analyses.

Conclusions:

  • Proton pump inhibitor (PPI) use is associated with an increased incidence of gastric cancer.
  • Despite a low absolute risk, long-term PPI therapy necessitates cautious consideration, particularly in low-risk gastric cancer regions.